SWORD 1&2: maintenance or improvement in renal function in PLWH through 148 weeks after switch to the dolutegravir plus rilpivirine 2-drug regimen
Por:
Llibre, JM, Voronin, E, Rubio, R, Girard, PM, Bredeek, F, van Wyk, J, Kahl, L, Jones, B, Curtis, L, Wynne, B, Nascimento, M, Koteff, J, Gartland, M, Angelis, K, Vandermeulen, K and Smith, KY
Publicada:
1 nov 2019
Resumen:
Filiaciones:
:
Univ Hosp Germans Trias, Barcelona, Spain
Fight AIDS Fdn, Barcelona, Spain
Voronin, E:
Hosp Infect Dis, St Petersburg, Russia
Rubio, R:
Dept Internal Med, HIV Unit, Madrid, Spain
Girard, PM:
St Antoine Hosp, AP HP, Paris, France
Bredeek, F:
Metropolis Med Grp, San Francisco, CA USA
van Wyk, J:
ViiV Healthcare, Brentford, England
Kahl, L:
ViiV Healthcare, Brentford, England
Jones, B:
ViiV Healthcare, Brentford, England
Curtis, L:
GlaxoSmithKline, Uxbridge, Middx, England
Wynne, B:
ViiV Healthcare, Res Triangle Pk, NC USA
Nascimento, M:
ViiV Healthcare, Brentford, England
Koteff, J:
ViiV Healthcare, Res Triangle Pk, NC USA
Gartland, M:
ViiV Healthcare, Res Triangle Pk, NC USA
Angelis, K:
GlaxoSmithKline, Uxbridge, Middx, England
Vandermeulen, K:
Janssen Res & Dev, Beerse, Belgium
Smith, KY:
ViiV Healthcare, Res Triangle Pk, NC USA
|